Every 10-Q that Vaxcyte, Inc. (PCVX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PCVX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PCVX filings page.
Vaxcyte, Inc. is a clinical-stage vaccine company developing pneumococcal conjugate vaccines VAX-31, VAX-24 and VAX-XL, plus programs for Group A Strep (VAX-A1) and Shigella (VAX-GI) using a cell-free protein synthesis platform. Multiple Phase 3 adult and Phase 2 infant trials of VAX-31 are underway or fully enrolled, and a first-in-human Phase 1 study of VAX-A1 began in June 2026.
For the quarter ended June 30, 2026, net loss was $284.3 million (vs. $166.6 million a year earlier), or $1.97 per share, driven primarily by research and development expense of $267.9 million. For the first six months, net loss was $604.9 million on operating expenses of $648.6 million, including $580.6 million in R&D and $68.0 million in general and administrative costs. Operating activities used $513.1 million of cash in the half.
Vaxcyte strengthened its balance sheet with a February 2026 underwritten offering that generated $601.8 million in net proceeds. As of June 30, 2026, cash, cash equivalents and investments totaled about $2.5 billion, which the company states will fund operating and capital needs for at least 12 months. The company is investing heavily in commercial-scale manufacturing, including a long-term Lonza suite in Switzerland and a Thermo Fisher drug-product agreement, and has non-cancelable manufacturing and raw material purchase commitments of $670.2 million.
Vaxcyte, Inc. reported a larger quarterly loss as it accelerates late‑stage vaccine development and manufacturing build‑out. For the three months ended March 31, 2026, net loss widened to $320.6 million, or $2.30 per share, from $140.7 million a year earlier, driven mainly by a sharp rise in research and development spending.
R&D expenses more than doubled to $312.8 million as the company advanced its 31‑valent pneumococcal conjugate vaccine VAX‑31 through multiple Phase 3 adult trials and a Phase 2 infant study, while progressing its Group A Strep candidate VAX‑A1 toward a Phase 1 start. General and administrative costs were stable at $33.1 million.
Vaxcyte ended the quarter with $2.7 billion in cash, cash equivalents and investments and stockholders’ equity of $3.0 billion, bolstered by $601.8 million in net proceeds from a February 2026 follow‑on offering. Operating activities used $280.6 million of cash in the quarter. Management states this liquidity should fund operating and capital needs for at least 12 months.
Vaxcyte (PCVX) reported Q3 2025 financial results. The company posted a net loss of $212.8 million, driven by higher operating expenses as R&D rose to $209.9 million and G&A reached $32.4 million. Year-to-date, net loss was $520.1 million.
Liquidity remains strong with $2.67 billion in cash, cash equivalents and investments as of September 30, 2025 (cash and cash equivalents $281.1 million, short‑term investments $1.43 billion, long‑term investments $959.3 million). Operating cash use totaled $430.7 million for the first nine months.
Vaxcyte expanded manufacturing capacity and supply: it maintains a long‑term arrangement with Lonza and, on September 24, 2025, entered a 15‑year commercial manufacturing agreement with Thermo Fisher for drug product. Non‑cancelable purchase commitments to key manufacturing partners totaled $631.7 million. Shares outstanding were 130,029,111 at September 30, 2025 and 130,906,263 at October 31, 2025.
Q2 2025 highlights from Vaxcyte, Inc. (PCVX) 10-Q. The company reported consolidated total assets of $3,305,363 and a six-month net loss of $307,291 (YTD), including a Q2 net loss of $166,573. Cash and cash equivalents declined to $306,744 at June 30, 2025 from $387,878 at December 31, 2024. Short-term and long-term investments totaled $2,519,774 (fair value).
Operating results and cash flow: R&D expense rose to $194,179 in Q2 2025 (Q2 2024: $131,507) and G&A to $32,040 (Q2 2024: $21,474), driving total operating expenses of $226,219 for the quarter. Net loss per share was $(1.22) for Q2 and $(2.26) for the six months. Net cash used in operating activities was $287,440 for the six months.
- Shares outstanding: 129,816,472 at June 30, 2025.
- Manufacturing buildout: $196.3M capital expenditures (company-owned) and $94.3M facility buildout expenditures owned/controlled by Lonza (including CHF27M repurposing fee).
- Commitments: $484,543K non-cancelable purchase commitments to manufacturing partners; lease liabilities total $85,845K (discounted).